Catalyst Calendar

Thu, Sep 24, 2026

1 updates

7:00 AM

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company’s website SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company

Presentation / Abstract • Phase 3Psych Congress poster presentation Thu, Sep 24, 2026vistagen.com

Tue, Sep 22, 2026

1 updates

VTGN

8:30 AM

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and patient-reported scales

Interim Data • Phase 3Interim data Tue, Sep 22, 2026vistagen.com

Thu, Sep 10, 2026

1 updates

VTGN

8:30 AM

Vistagen to Present at Psych Congress 2026

Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging

Presentation / Abstract • Phase 3Poster presentation Thu, Sep 17, 2026vistagen.com